Drugs / Recombinant HBsAg
last change Nov 1995 re-read 2 minutes ago

Recombinant HBsAg

Vaccine

Developed for
hepatitis B virus infection
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00697242 Jan 1994 → Nov 1995 hepatitis B virus infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Recombinant HBsAg ClinicalTrials.gov intervention name — accepted as the source's own label NCT00697242
Modality Vaccine “recombinant hepatitis B vaccines with and without MPL” NCT00697242
Route Intramuscular Intramuscular injection, 3 doses” NCT00697242